

1 **Research article**

2 **Fluoroquinolone-resistant *Escherichia coli* carriage in transrectal prostate biopsy**  
3 **patients without infectious complications**

4 Sofia Kalinen<sup>a†</sup>, Heini Kallio<sup>a†</sup>, Juha Knaapila<sup>b</sup>, Teemu Kallonen<sup>c,a</sup>, Eveliina Munukka<sup>a,c</sup>,  
5 Tarja Lamminen<sup>b</sup>, Pentti Huovinen<sup>a,b</sup>, Peter J. Boström<sup>b</sup>, Antti J. Hakanen<sup>c,a</sup> and Marianne  
6 Gunell<sup>c,a\*</sup>

7 <sup>a</sup>Medical Microbiology and Immunology, Institute of Biomedicine, University of Turku,  
8 Turku, Finland;

9 <sup>b</sup>Department of Urology, Turku University Hospital, Turku, Finland;

10 <sup>c</sup>Department of Clinical Microbiology, Laboratory Division, Turku University Hospital,  
11 Turku, Finland.

12

13 \*Corresponding author. Clinical microbiology, Turku University Hospital, Kiinamylynkatu  
14 10, 20520 Turku, Finland, tel: +358-46-922 1871, email: [marianne.gunell@tyks.fi](mailto:marianne.gunell@tyks.fi)

15 †These authors contributed equally to this article.

16

17 Running title: FQ-resistant *E. coli* in TRUS-Bx patients

18 Keywords: Ciprofloxacin-resistant, *E. coli*, TRUS-Bx, prophylaxis, resistance mechanisms

19

20 **Abstract**

21 Fluoroquinolones are a commonly used prophylaxis in transrectal ultrasound-guided  
22 prostate biopsy (TRUS-Bx), even though fluoroquinolone-resistant *Escherichia coli* has  
23 been associated with infectious complications after TRUS-Bx. The present study describes  
24 fluoroquinolone resistance mechanisms and antimicrobial susceptibility among intestinal *E.*  
25 *coli*, isolated from TRUS-Bx patients in a prospective study showing very few infectious  
26 prostate biopsy adverse events. This Multi-IMPROD sub-study included a total of 336  
27 patients who received either ciprofloxacin, levofloxacin, or fosfomycin as prophylaxis  
28 before TRUS-Bx. *E. coli* could be cultured from 278 fecal swab samples, and 27 (9.7%) of  
29 these showed resistance to ciprofloxacin, and 14 (5.0%) were susceptible with increased  
30 exposure (I). Chromosomal and transferable fluoroquinolone resistance mechanisms were  
31 found among ciprofloxacin non-susceptible isolates, but both *qnr* genes and single *gyrA*  
32 mutations were found also among the ciprofloxacin-susceptible *E. coli* population. Low-  
33 level fluoroquinolone resistance is commonly associated with ESBL production in  
34 *Enterobacterales*. However, ESBL and *qnr* genes were not associated in our material, 14  
35 isolates were ESBL producers and only 14.3% of them had the *qnr* gene, although 85.7%  
36 of the ESBL producers were ciprofloxacin non-susceptible. In the Multi-IMPROD substudy,  
37 only two mild urinary tract infections were reported, indicating that the antimicrobial  
38 susceptibility or resistance pattern of *E. coli* does not correlate with the onset of post-  
39 biopsy adverse events. We conclude that in our clinical settings, ciprofloxacin and  
40 levofloxacin prophylaxis is effective, and no severe post-biopsy infections were detected  
41 despite the intestinal colonization of genotypically and phenotypically fluoroquinolone-  
42 resistant *E. coli*.

43

## 44 Introduction

45 Prostate cancer is one of the most common cancer types in men, especially in Western  
46 countries. A prostate cancer diagnosis is based on transrectal ultrasound-guided prostate  
47 biopsy (TRUS-Bx) which is an invasive procedure, and antimicrobial prophylaxis is a  
48 common practice to lower the risk for infectious adverse events. Fluoroquinolones are  
49 widely used prophylaxis in prostate biopsy procedures, due to their good penetration to  
50 prostate tissue (1). Fluoroquinolone resistance has emerged globally during the last  
51 decades, and both fluoroquinolone-resistant *Escherichia coli* and isolates with reduced  
52 susceptibility have increasingly reported to cause sepsis or other infectious adverse events  
53 after prostate biopsy procedure (2-6). In Finland, fluoroquinolones are very common per  
54 oral treatment for urinary tract infections in men. Fluoroquinolone resistance in both urine  
55 and blood *E. coli* isolates has increased during the last decade, being 15.1% and 10.8%,  
56 respectively in Finres data of 2020 (7). The percentage of ESBL-producing *E. coli* has also  
57 increased during the last decade being 6.5% in men's urine isolates and 6.6% in blood  
58 isolates in 2020 (7). In *Enterobacterales*, low-level fluoroquinolone resistance has been  
59 associated with ESBL production (8-11), and in Finland, 2.3% of the urine *E. coli* isolates  
60 were both ESBL producers and fluoroquinolone-resistant in 2020 (7). Low-level  
61 fluoroquinolone resistance is mainly caused by plasmid-mediated quinolone resistance  
62 (PMQR) determinants like *qnr* genes whereas high-level resistance is caused by several  
63 chromosomal mutations in the quinolone resistance determining region (QRDR) of DNA  
64 gyrase (*gyrA/gyrB*) and topoisomerase IV genes (*parC/parE*) (12-14). In *E. coli*, resistance  
65 to fluoroquinolones is highly associated with mutations in *gyrA* (12). In the present study,  
66 we determined the correlation between prostate biopsy adverse events, fluoroquinolone  
67 resistance mechanisms and antimicrobial susceptibility among intestinal *E. coli* isolated  
68 from fecal swab samples from men undergoing TRUS-Bx procedure in Finland.

## 69 **Methods**

70 *Study population.* This study is a substudy of IMPROD (Improved Prostate Cancer  
71 Diagnosis – Combination of Magnetic Resonance Imaging (MRI) and Biomarkers,  
72 NCT02241122) multi-center study (15). A prostate cancer screen with TRUS-Bx was  
73 performed for patients included in this study and a rectal swab sample was taken during  
74 the biopsy procedure. Between March 2015 and May 2017, a total of 336 rectal swab  
75 samples were collected from four hospitals in Finland: Helsinki University Hospital, 58  
76 samples; Tampere University Hospital, 59 samples; Satakunta Central Hospital, 87  
77 samples; and Turku University Hospital, 132 samples. Levofloxacin was used as  
78 antimicrobial prophylaxis in Turku, and ciprofloxacin in all the other study sites. In Helsinki,  
79 patients who had traveled abroad within three months before the TRUS-Bx received  
80 fosfomycin instead of ciprofloxacin.

81 *Bacterial cultures.* Swab samples were cultured on ChromAgar Orientation plate (Becton  
82 Dickinson, Heidelberg, Germany) and 5 µg-ciprofloxacin disk (OXOID, Thermo Scientific,  
83 Helsinki, Finland) was placed on top of the culture to select the patient's most resistant *E.*  
84 *coli* strain. After the overnight incubation at 35 °C, two to three bacterial colonies with *E.*  
85 *coli* morphology (mauve to light purple colonies) were selected preferably near to the  
86 ciprofloxacin disk and pure cultures were made from these on CLED plates (Becton  
87 Dickinson, Heidelberg, Germany). Maldi-TOF (Bruker, Berlin, Germany) was used for  
88 species identification of the isolated strains. Only *E. coli* isolates were studied further.

89 *Antimicrobial susceptibility testing.* Antimicrobial susceptibility testing was performed with  
90 the disk diffusion method, according to EUCAST guidelines (16). Following antimicrobial  
91 disks were used: ciprofloxacin 5 µg, levofloxacin 5 µg, cefotaxime 5 µg, ceftazidime 10 µg,  
92 cefoxitin 30 µg, meropenem 10 µg, ampicillin 10 µg, amoxicillin-clavulanic acid 10/20 µg,  
93 mecillinam 10 µg, nitrofurantoin 300 µg, trimethoprim 5 µg, and trimethoprim-

94 sulfamethoxazole 25 µg (OXOID, Thermo Scientific, Helsinki, Finland). Antimicrobial  
95 susceptibility profiles of each *E. coli* isolates were determined according to EUCAST  
96 clinical breakpoint table version 11.0 2021 (17). *E. coli* ATCC 25922 was used as a control  
97 strain in antimicrobial susceptibility testing.

98 *PCR amplification and sequencing of chromosomal gyrA and parC gene mutations.*

99 Fluoroquinolone resistance mechanisms were studied in all *E. coli* isolates with a  
100 ciprofloxacin (CIP) disk inhibition zone ≤30mm. PCR amplification of *gyrA* and *parC* genes  
101 were performed with primers described in Table 1. The *gyrA/parC* PCR reaction (50 µL)  
102 consisted of 0.2 pmol/µL of each primer, 0.03 U/µL AmpliTaq Gold DNA polymerase, 5 µL  
103 AmpliTaq Gold buffer, 2 mM MgCl<sub>2</sub> (Thermo Fisher Scientific Oy, Vantaa, Finland), and  
104 0.2 mM dNTP mix (Life Technologies Europe, Espoo, Finland). The PCR program  
105 consisted of an initial denaturation at 94°C for 10 minutes, then 37 cycles of DNA  
106 denaturation at 94°C for 30 seconds, primer annealing at 55°C for 30 seconds, and  
107 extension at 72°C for 90 seconds. PCR-products were purified enzymatically with  
108 Exonuclease I- and FastAp Thermosensitive alkaline phosphatase -enzymes (Thermo  
109 Fisher Scientific Oy, Vantaa, Finland), and sequenced with BigDye v.3.1 sequencing using  
110 ABI3730xl DNA Analyzer at Institute for Molecular Medicine (FIMM, Helsinki, Finland).

111 *Detection of plasmid-mediated quinolone resistance genes.* Transferable plasmid-  
112 mediated quinolone resistance (PMQR) *qnr* genes were screened for all the *E. coli* isolates  
113 with a ciprofloxacin disk inhibition zone ≤30mm. In addition, 34/90 randomly selected  
114 isolates with a ciprofloxacin inhibition zone >30mm were studied with previously reported  
115 primers and protocols (18).

116 *Detection of ESBL genes.* Possible ESBL producers were screened according to EUCAST  
117 guidelines on the detection of Resistance mechanisms (19). ESBL + AmpC confirmation  
118 Kit (Rosco Diagnostics) was used to confirm ESBL production from *E. coli* isolates with

119 reduced cefotaxime and ceftazidime susceptibility, inhibition zone <21 and <22mm,  
120 respectively. ESBL genes (*bla*<sub>CTX-M</sub>, *bla*<sub>SHV</sub> and *bla*<sub>TEM</sub>) were screened from these same  
121 isolates using previously described primers and PCR protocols (20).

## 122 **Results**

123 *Antimicrobial susceptibility profiles.* *E. coli* could be isolated from 278 patient samples (out  
124 of 336 fecal samples). The highest resistance rates were detected against ampicillin and  
125 amoxicillin-clavulanate (27.7% and 24.1%, respectively), also trimethoprim resistance was  
126 quite common (14.0%) (Figure 1). Totally 27 (9.7 %) *E. coli* strains were ciprofloxacin-  
127 resistant i.e. disk inhibition zone was <22mm and 14 (5.0 %) strains were ciprofloxacin-  
128 susceptible with increased exposure (I, CIP inhibition zone 22-24mm), according to the  
129 2021 EUCAST breakpoints (17). Furthermore 22 (7.9%) *E. coli* strains were levofloxacin-  
130 resistant (R) (Figure 1). With correlation to given prophylaxis, 11 (9.6%) isolates from the  
131 levofloxacin group were resistant to both ciprofloxacin and levofloxacin, and six (5.3%) and  
132 four (3.5%) were ciprofloxacin- and levofloxacin-susceptible with increased exposure (I),  
133 respectively. Among the ciprofloxacin group, 16 (9.8%) and 11 (6.7%) isolates were  
134 ciprofloxacin and levofloxacin R, respectively, and eight (4.9%) and 11 (6.7%) isolates  
135 were ciprofloxacin and levofloxacin I, respectively.

136 Resistance against cefotaxime and ceftazidime was detected in 14 (5.0%) and 13 (4.7%)  
137 *E. coli* isolates. Of the ciprofloxacin-resistant *E. coli* isolates, nine (3.2%) were cefotaxime-  
138 resistant, and eleven (4.0%) showed co-resistance to trimethoprim. These eleven strains  
139 were also resistant to ampicillin and sulfamethoxazole-trimethoprim. Four of these were  
140 also gentamicin-resistant and three of these were ESBL producing strains. Ten  
141 ciprofloxacin-resistant *E. coli* (3.6%) were also ESBL producers and five (1.8%) isolates  
142 were both trimethoprim-resistant and ESBL producers. Antimicrobial susceptibility results  
143 from all tested antimicrobials are presented in Figure 1.

144 *Fluoroquinolone resistance mechanisms and ESBL producers.* Fluoroquinolone resistance  
145 mechanisms were found in all fluoroquinolone-non-susceptible isolates, i.e. CIP disk  
146 inhibition zone <25mm (17). Of the ciprofloxacin-resistant isolates, 23 had point mutations  
147 in the QRDR of both *gyrA* and *parC*, and four had point mutations only in *gyrA*. The most  
148 common *gyrA* mutation was S83L + D87N –double mutation found in 20 isolates, nine of  
149 these had also S80I + E84G –double mutation, and ten had S80I –single mutation in *parC*  
150 (Figure 2). Of the 14 *E. coli* isolates being ciprofloxacin I (susceptible with increased dose,  
151 according to EUCAST (17), disk inhibition zone 22-24mm), ten had S83L –single mutation  
152 and one had D87Y –single mutation in the QRDR of *gyrA*, and three isolates had only *qnr*  
153 gene (*qnrA/B*) as their only fluoroquinolone-resistance mechanism detected.

154 Fluoroquinolone resistance mechanisms were also found among ciprofloxacin-susceptible  
155 isolates. A total of seven isolates with ciprofloxacin inhibition zone between 25-29mm had  
156 a single *gyrA* mutation, and 31 isolates had *qnr* gene. The distribution of fluoroquinolone  
157 resistance mechanisms among the tested *E. coli* population is presented in Figure 2.

158 According to EUCAST Detection of resistance mechanisms guideline (19), 15 *E. coli*  
159 isolates (5.4%) were ESBL producers, nine of these were positive for *bla*<sub>CTX-M</sub> gene, four  
160 for *bla*<sub>CTX-M</sub>+*bla*<sub>TEM</sub>, and one strain for *bla*<sub>SHV</sub>+*bla*<sub>TEM</sub>. One screening positive isolate did  
161 not have any of these three ESBL genes analyzed. Of the ESBL *E. coli* strains, ten were  
162 ciprofloxacin-resistant and had chromosomal mutations, two were ciprofloxacin susceptible  
163 with increased dose, one of them had *qnrS* gene and the other had a single *gyrA* mutation.  
164 Two of the ESBL strains were ciprofloxacin-susceptible, but one of these had a single *gyrA*  
165 mutation. The distribution of ESBL genes and fluoroquinolone resistance mechanisms is  
166 presented in Figure 2.

167 *Fluoroquinolone susceptibility and resistance mechanisms in correlation to post-biopsy*  
168 *adverse events*

169 In the Multi-IMPROD study, only 12 minor post-biopsy adverse events were reported.<sup>21</sup>

170 The list of complications, prophylaxis, and microbiological findings, including ciprofloxacin  
171 susceptibility and possible resistance mechanisms of these 12 patients' are presented in  
172 Table 2.

## 173 **Discussion**

174 In the present study, the antimicrobial susceptibility and fluoroquinolone resistance  
175 mechanisms of intestinal *E. coli*, isolated from faecal swab samples from men undergoing  
176 prostate biopsy procedures were analysed. Post-biopsy infections are a common side  
177 effect of prostate biopsy procedures, and especially fluoroquinolone-resistant and  
178 multidrug-resistant *E. coli* has been reported of being the main factor for infectious adverse  
179 events (2-5, 22). Our results showed that 14.7% of the tested *E. coli* strains were  
180 ciprofloxacin non-susceptible, and 85.3% were susceptible according to EUCAST  
181 breakpoints (17). If CLSI breakpoints would have been used the number of ciprofloxacin-  
182 resistant strains would have been the same (CIP  $\leq$ 21mm), whereas the ciprofloxacin I  
183 isolates would have increased from 14 to 19 isolates (CIP 22-25mm vs. CIP 22-24mm)  
184 (23). Resistance to levofloxacin was more common in the study population who got  
185 levofloxacin prophylaxis than in ciprofloxacin prophylaxis group (9.6% vs. 6.7%,  
186 respectively), whereas ciprofloxacin resistance was practically equal in both groups (9.6%  
187 vs. 9.8%, respectively). Of the ciprofloxacin-resistant *E. coli*, 4.0% showed co-resistance to  
188 trimethoprim, 3.6% of were ciprofloxacin-resistant and ESBL producers, and 1.8% were  
189 ciprofloxacin- and trimethoprim-resistant and ESBL producers. Compared to overall  
190 susceptibility levels of *E. coli* isolates in Finland in 2020, fluoroquinolone resistance among  
191 the study population was higher compared to invasive isolates (10.8%), but equal to  
192 resistance levels in urine isolates (15.1%) (7). ESBL percentage among the intestinal *E.*  
193 *coli* isolates was somewhat higher, 5.4%, compared to the earlier reported ESBL carriage



194 rate (4.7%) in Finland (24), but lower compared to ESBL-positivity rate in urine *E. coli* –  
195 isolates (6.5%) (7). In addition, resistance to trimethoprim was lower, whereas multidrug  
196 resistance was more common compared to that reported in Finres 2020 (7).

197 To become a high-level fluoroquinolone-resistant, bacterial strain needs to have mutations  
198 in both QRDR of *gyrA* and *parC*, however mutation even in one of these gene targets,  
199 S83L in *gyrA*, S80I in *parC*, and D87N in *gyrA* can cause a clinically relevant  
200 fluoroquinolone resistance in *E. coli* (25). In our study, double *gyrA+parC* mutations were  
201 detected only in high-level resistant isolates whereas single *gyrA* mutations were detected  
202 even phenotypically ciprofloxacin-susceptible isolates. EUCAST has started using the term  
203 ATU (Area of Technical Uncertainty) to warn laboratories that, there can be interpretative  
204 difficulties with susceptibility test results in this area, and susceptibility interpretation  
205 should be carefully evaluated (26). According to EUCAST breakpoints for ciprofloxacin  
206 (17), the ATU area is situated between the resistant and susceptible populations (22-  
207 24mm), i.e. I area, and includes the isolates which can be considered susceptible with  
208 increased exposure. As we show in Figure 2, isolates within the area of technical  
209 uncertainty, have chromosomal gyrase mutations, indicating that it is justified to consider  
210 these isolates rather resistant than susceptible. PMQR determinants like *qnr* genes are  
211 linked to low-level fluoroquinolone resistance but these genes also enhance the selection  
212 of high-level resistance, furthermore, the *qnr* genes are also easily missed until further  
213 mechanisms are acquired and detected (11-12,14, 27-28). We show that the *qnr* genes  
214 were detected among ciprofloxacin-resistant, ciprofloxacin I, and ciprofloxacin-susceptible  
215 strains, indicating that *qnr* genes do not necessarily have a clinical relevance without  
216 additional resistance mechanisms (25). PMQR genes are associated with the same  
217 plasmids as ESBL genes (9-11, 27) and there are reports on post-biopsy infections linked  
218 to ESBL *E. coli* isolates with co-resistance to fluoroquinolones (29). In our study, 85.7% of

219 the ESBL strains had chromosomal mutations in QRDR and only one ESBL strain had a  
220 PMQR gene as the only fluoroquinolone resistance mechanism, indicating that ESBL-  
221 producing strains and strains with *qnr* genes were not associated in our material. In  
222 addition, among the tested ciprofloxacin-susceptible *E. coli* isolates with disk inhibition  
223 zone 31-36mm, no fluoroquinolone resistance determinants were detected, as expected.  
224 Despite the ciprofloxacin and multidrug resistance detected in our study population, no  
225 severe post-biopsy infections were reported in the Multi-IMPROD study (21). It is known,  
226 that the use of fluoroquinolones increases the risk for intestinal colonization of  
227 fluoroquinolone-resistant *E. coli*, and further post-biopsy infectious complications (6,30). In  
228 the present study, there were both phenotypically ciprofloxacin-resistant *E. coli* and  
229 isolates with susceptible phenotype but having fluoroquinolone resistance mechanisms,  
230 and despite this, only two mild UTI cases were reported. One of them had ciprofloxacin-  
231 susceptible *E. coli* in a swab sample, and the other had ciprofloxacin I *E. coli* with a single  
232 *gyrA* mutation, indicating that fluoroquinolone resistance alone does not explain the  
233 possible adverse events after TRUS-Bx. There are reports on certain *E. coli* clones, such  
234 as ST131 that have spread widely and have caused severe infections (3), and thus further  
235 studies are needed to evaluate the role of virulence factors and other resistance  
236 mechanisms such as efflux pumps, in post-biopsy infections.

### 237 **Conclusion:**

238 We show in this study that fluoroquinolone resistance mechanisms, both the *qnr* genes  
239 and *gyrA* mutations, were also found among the ciprofloxacin-susceptible *E. coli*  
240 population and that ESBL and transferable *qnr* genes were not associated in our material.  
241 We conclude that the onset of post-biopsy adverse events did not correlate with  
242 antimicrobial susceptibility, since no severe post-biopsy infections were detected despite

243 the intestinal colonization of genotypically and phenotypically fluoroquinolone-resistant *E.*

244 *coli*.

245

246 **Acknowledgments**

247 We thank Minna Lamppu for her skillful technical assistance with cultured *E. coli* isolates

248 **Funding**

249 This study was funded by the Sigrid Juselius Foundation (for Peter J. Boström), and  
250 Finnish Governmental Special Funding, The Cancer Foundation Finland, University of  
251 Turku Combined Research Funding, and the Turku University Hospital Foundation (for  
252 Juha Knaapila).

253 **Conflict of Interest**

254 All authors declare no conflict of interest regarding this publication.

255 **Transparency declarations**

256 None to declare

## 257 **References**

- 258       1. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate  
259       biopsy. *Cochrane Database Syst Rev* 2011;(5):CD006576. doi:  
260       10.1002/14651858.CD006576.pub2. PMID: 21563156.
- 261       2. Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant *Escherichia coli*  
262       after transrectal ultrasound-guided prostate needle biopsy. *Urology* 2009;74(2):332-8. doi:  
263       10.1016/j.urology.2008.12.078. Epub 2009 May 22. PMID: 19464041.
- 264       3. Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M,  
265       Freeman JT. *Escherichia coli* bloodstream infection after transrectal ultrasound-guided  
266       prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major  
267       causative pathogen. *Clin Infect Dis* 2012;54(10):1406-12. doi: 10.1093/cid/cis194. Epub  
268       2012 Mar 14. PMID: 22419681.
- 269       4. Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR,  
270       Semjonow A, Strolin P, Montesino MF, Berge V, Roobol MJ, and Rannikko A.  
271       Complications after prostate biopsies in men on active surveillance and its effects on  
272       receiving further biopsies in the Prostate cancer Research International: Active Surveillance  
273       (PRIAS) study. *BJU Int* 2016; 118:366-371. doi: 10.1111/bju.13410 [doi].
- 274       5. Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, and Verhaegen J.  
275       Fluoroquinolone-resistant *E. coli* in intestinal flora of patients undergoing transrectal  
276       ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic  
277       prophylaxis? *Clin Microbiol Infect* 2012 18:575-581. doi: 10.1111/j.1469-0691.2011.03638.x  
278       [doi].
- 279       6. Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A.  
280       Rectal *E. coli* above ciprofloxacin ECOFF associate with infectious complications following  
281       prostate biopsy. *Eur J Clin Microbiol Infect Dis* 2018 Jun;37(6):1055-1060. doi:  
282       10.1007/s10096-018-3217-7. Epub 2018 Mar 2. PMID: 29500572.

- 283 7. Räisänen K, Ilmavirta H, Vuento R, Hakanen AJ, Salmenlinna S, Gunell M, Jalava J,  
284 Rantakokko-Jalava K, Wuorela M, Hyyryläinen HL, Mentula S, Pätäri-Sampo A, Toropainen  
285 M, Seiskari T. Bakteerien mikrobilääkeresistenssi Suomessa: Finres 2020. Työpaperi:  
286 2021\_029. (In Finnish, Figures also in English). THL Terveystieteiden tutkimuskeskus.  
287 <https://urn.fi/URN:ISBN:978-952-343-758-6>
- 288 8. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of  
289 plasmid-mediated quinolone resistance *qnr* genes in ESBL-producing enterobacterial  
290 isolates. *J Antimicrob Chemother* 2007; Volume 60, Issue 2: 394–  
291 397, <https://doi.org/10.1093/jac/dkm204>
- 292 9. Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, Li L. Plasmid-mediated quinolone resistance  
293 determinants *qnr* and *aac(6)-Ib-cr* in extended-spectrum  $\beta$ -lactamase-  
294 producing *Escherichia coli* and *Klebsiella pneumoniae* in China. *J Antimicrob Chemother*  
295 2008; Volume 61, Issue 5: 1003–1006, <https://doi.org/10.1093/jac/dkn063>
- 296 10. Veldman K, Dierikx C, van Essen-Zandbergen A, van Pelt W, Mevius D. Characterization of  
297 multidrug-resistant, *qnrB2*-positive and extended-spectrum- $\beta$ -lactamase-  
298 producing *Salmonella* Concord and *Salmonella* Senftenberg isolates. *J Antimicrob*  
299 *Chemother* 2010; Volume 65, Issue 5: 872–875, <https://doi.org/10.1093/jac/dkq049>
- 300 11. Gunell M, Aulu L, Jalava J, Lukinmaa-Åberg S, Österblad M, Ollgren J, Huovinen P,  
301 Siitonen A, Hakanen AJ. Cefotaxime-resistant *Salmonella enterica* in travelers returning  
302 from Thailand to Finland. *Emerg Infect Dis* 2014 Jul;20(7): 1214-7. doi:  
303 10.3201/eid2007.131744. PMID: 24960266; PMCID: PMC4073843.
- 304 12. Hooper DC. Mechanisms of fluoroquinolone resistance. *Drug Resist Updat* 1999;2(1):38-  
305 55. doi: 10.1054/drup.1998.0068. PMID: 11504468.
- 306 13. Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, Huovinen P, Siitonen  
307 A, Hakanen AJ, Piddock LJ. Mechanisms of resistance in nontyphoidal *Salmonella enterica*  
308 strains exhibiting a nonclassical quinolone resistance phenotype. *Antimicrob Agents*  
309 *Chemother* 2009;53(9):3832-6. doi: 10.1128/AAC.00121-09. Epub 2009 Jul 13. PMID:  
310 19596880; PMCID: PMC2737843.

- 311 **14.** Hooper DC, Jacoby GA. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action  
312 and Resistance. *Cold Spring Harb Perspect Med* 2016; Sep 1;6(9):a025320. doi:  
313 10.1101/cshperspect.a025320. PMID: 27449972; PMCID: PMC5008060.
- 314 **15.** Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T,  
315 Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström  
316 PJ. Antibiotic susceptibility of intestinal *Escherichia coli* in men undergoing transrectal  
317 prostate biopsies: a prospective, registered, multicentre study. *BJU Int* 2018;122(2):203-  
318 210. doi: 10.1111/bju.14198. Epub 2018 Apr 6. PMID: 29533507.
- 319 **16.** European Committee on Antimicrobial Susceptibility Testing. 2015. Antimicrobial  
320 susceptibility testing. EUCAST disk diffusion method. Manual version 5.0.  
321 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Disk\\_test\\_documents/Man](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Manual_v_5.0_EUCAST_Disk_Test.pdf)  
322 [ual\\_v\\_5.0\\_EUCAST\\_Disk\\_Test.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Manual_v_5.0_EUCAST_Disk_Test.pdf)
- 323 **17.** European Committee on Antimicrobial Susceptibility Testing. 2021. The European  
324 Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of  
325 MICs and zone diameters, version 11.0.  
326 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_11.0](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf)  
327 [\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf)
- 328 **18.** Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in  
329 ceftazidime-resistant *Enterobacteriaceae* isolates from the United States. *Antimicrob*  
330 *Agents Chemother* 2006;50(8):2872-4. doi: 10.1128/AAC.01647-05. PMID: 16870791;  
331 PMCID: PMC1538681.
- 332 **19.** European Committee on Antimicrobial Susceptibility Testing. 2017. The EUCAST guideline  
333 on detection of resistance mechanisms, version 2.0.  
334 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Resistance\\_mechanisms/](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf)  
335 [EUCAST\\_detection\\_of\\_resistance\\_mechanisms\\_170711.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf)
- 336 **20.** Nyberg SD, Österblad M, Hakanen AJ, Huovinen P, Jalava J, and The Finnish Study Group  
337 For Antimicrobial Resistance. Detection and molecular genetics of extended-spectrum

- 338 beta-lactamases among cefuroxime-resistant *Escherichia coli* and *Klebsiella* spp. isolates  
339 from Finland, 2002-2004. *Scand J Infect Dis* 2007; 39:417-424. doi: 777680054 [pii].
- 340 **21.** Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M,  
341 Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, and Boström PJ.  
342 Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate  
343 Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.  
344 *Eur Urol Focus* 2019;5(3):443-448. doi: 10.1016/j.euf.2017.12.001. Epub 2017 Dec 20.  
345 PMID: 29275146.
- 346 **22.** Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious  
347 complications following transrectal ultrasound-guided prostate biopsy: new challenges in  
348 the era of multidrug-resistant *Escherichia coli*. *Clin Infect Dis* 2013;57(2):267-74. doi:  
349 10.1093/cid/cit193. Epub 2013 Mar 26. PMID: 23532481.
- 350 **23.** Clinical and Laboratory Standards Institute. 2020. Performance Standards for Antimicrobial  
351 Susceptibility testing: M100-ED30:2020. CLSI, Wayne, PA, USA.
- 352 **24.** Ny S, Kozlov R, Dumpis U, Edquist P, Gröndahl-Yli-Hannuksela K, Kling AM, Lis DO,  
353 Lubbert C, Pomorska-Wesolowska M, Palagin I, Vilde A, Vuopio J, Walter J, Wisell KT and  
354 NoDARS ESBL-carrier working group. Large variation in ESBL-producing *Escherichia coli*  
355 carriers in six European countries including Russia. *Eur J Clin Microbiol Infect Dis* 2018;  
356 37:2347-2354. doi: 10.1007/s10096-018-3382-8 [doi].
- 357 **25.** Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D. Mutation Supply and  
358 Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant *Escherichia coli*. *Mol Biol*  
359 *Evol* 2017;34(5):1029-1039. doi: 10.1093/molbev/msx052. PMID: 28087782; PMCID:  
360 PMC5400412.
- 361 **26.** European Committee on Antimicrobial Susceptibility Testing. 2019. Area of Technical  
362 Uncertainty (ATU) in antimicrobial susceptibility testing.  
363 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Disk\\_test\\_documents/AT](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/ATU/Area_of_Technical_Uncertainty_-_guidance_2019.pdf)  
364 [U/Area\\_of\\_Technical\\_Uncertainty\\_-\\_guidance\\_2019.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/ATU/Area_of_Technical_Uncertainty_-_guidance_2019.pdf)



- 365       **27.** Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically  
366           significant problem? *Clin Microbiol Infect* 2008;14(4):295-7. doi: 10.1111/j.1469-  
367           0691.2007.01930.x. Epub 2008 Jan 7. PMID: 18190576.
- 368       **28.** Gunell M, Hakanen AJ, Jalava J, Huovinen P, Österblad M. Hidden qnrB12 gene in a  
369           Finnish faecal microbiota isolate from 1994. *J Antimicrob Chemother* 2009;64(4):861-2. doi:  
370           10.1093/jac/dkp304. Epub 2009 Aug 19. PMID: 19692413.
- 371       **29.** Korkmaz N, Gurbuz Y, Sandikci F, Kul G, Tutuncu EE, Sencan I. The Role of Ciprofloxacin  
372           Resistance and Extended-spectrum beta-lactamase (ESBL) Positivity in Infective  
373           Complications Following Prostate Biopsy. *Urol J*, 2020;17(2):192-197. doi:  
374           10.22037/uj.v0i0.4755. PMID: 31364100.
- 375       **30.** Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D,  
376           Machan L, Black P. Ciprofloxacin resistance in the faecal carriage of patients undergoing  
377           transrectal ultrasound guided prostate biopsy. *BJU Int* 2013;111(6):946-53. doi:  
378           10.1111/j.1464-410X.2012.11637.x. Epub 2013 Mar 6. PMID: 23464844.

379 Table 1. Primers used in *gyrA* and *parC* PCR and Sanger sequencing

Primer	Target	Sequence (5'-3')
Ecoli_gyrA_307_f	<i>gyrA</i>	AAGCCGGTACACCGTCGCGTACTT
Ecoli_gyrA_570_r	<i>gyrA</i>	TTTCGCCAGACGGATTTCCG
Ecoli_parC_172_f	<i>parC</i>	GTCTGAACTGGGCCTGAATGC
Ecoli_parC_321_r	<i>parC</i>	AGCGGATAACGGTAAGAGAACGG

380

381 Table 2. Patients with post-biopsy adverse events, used prophylaxis, ciprofloxacin

382 susceptibility testing results and resistance mechanisms detected.

Sample ID	Prophylaxis	Adverse event	E. coli	CIP disk inhibition zone (mm)	Susceptibility interpretation	FQ-resistance mechanism
TA-009	Ciprofloxacin	mild UTI	yes	24	I	S83L
TU-062	Levofloxacin	hematuria	yes	27	S	D87N
HE-056	Ciprofloxacin	hematuria	yes	28	S	<i>qnrA</i>
PO-071	Ciprofloxacin	urine retention	yes	28	S	-
PO-055	Ciprofloxacin	mild UTI	yes	29	S	-
TU-010	Levofloxacin	hematuria	yes	30	S	-
TU-054	Levofloxacin	hematuria	yes	30	S	-
HE-053	Ciprofloxacin	hematuria	yes	31	S	-
PO-075	Ciprofloxacin	urinary retention	yes	31	S	-
TU-146	Levofloxacin	rectal bleeding	yes	31	S	-

TU-026	Levofloxacin	hematuria	yes	32	S	-
HE-047	Ciprofloxacin	hematuria/ urinary retention	no	nd	nd	nd

383

384

385 Figure 1. Antimicrobial susceptibility profiles of 278 *E. coli*, isolated from fecal swab

386 samples taken from men undergoing TRUS-Bx

387 Figure 2. Fluoroquinolone (FQ) resistance mechanisms and ESBL genes detected among 276 *E. coli* isolates with ciprofloxacin  
388 (CIP) disk inhibition zone 6-30 mm. A dashed black line with R represents EUCAST and CLSI breakpoint (16, 23) for CIP-resistant  
389 isolates. A dashed line with black S represents the EUCAST breakpoint and a grey dashed line with S represents the CLSI  
390 breakpoint for CIP susceptible isolates.

391

392

393

394

395

396

397

398

399

400 R= resistant; S= susceptible

401 \*Randomly selected 34 isolates with disk inhibition zone 31-36mm were tested for *qnr* genes



